The Peptide Moment: How FDA's Regulatory Reversal Creates Risk and Opportunity for Venture Capital and Private Equity Guidepost Solutions BPC 157 for athletes and injury treatment: Science, safety, and legal concerns When will the FDA reclassify BPC 157 to Category 1? Odds & Predictions The Peptide Craze Part 2: BPC 157, NAD and the Truth Behind the Longevity Molecule Hype The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York BPC 157: Miracle Healing Peptide or Hidden Danger?